Evidence map›Paper›PMID 38488978›Full record

ReviewJournal of endocrinological investigation2024

Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).

D Rendina, A Falchetti, D Diacinti, F Bertoldo, D Merlotti, S Giannini, L Cianferotti, G Girasole, M Di Monaco, S Gonnelli and 8 more

Open access · hybridAbstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of endocrinological investigation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. MST4 as a key driver of osteoclast activation in osteoporosis.Journal of pharmaceutical analysis · 2026
    Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 9 institutions in 1 country.

D Rendina *Department of Clinical Medicine and Surgery, University of Naples "Federico II", 80138, Naples, Italy.ORCID http://orcid.org/0000-0002-0331-0392
A Falchetti *Department of Medical Biotechnology and Translational Medicine, University of Milan, 20122, Milan, Italy.ORCID http://orcid.org/0000-0002-6739-4417
D DiacintiDepartment of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, Viale Regina Elena 324, 00161, Rome, Italy.ORCID http://orcid.org/0000-0001-6894-3433
F BertoldoEmergency Medicine, Department of Medicine, University of Verona, 37129, Verona, Italy.ORCID http://orcid.org/0000-0002-5175-7340
D MerlottiDepartment of Medical Sciences, Azienda Ospedaliera Universitaria Senese, 53100, Siena, Italy.ORCID http://orcid.org/0000-0002-3338-6339
S GianniniClinica Medica 1, Department of Medicine, University of Padova, 35122, Padua, Italy.ORCID http://orcid.org/0000-0003-0796-9749
L CianferottiBone Metabolic Diseases Unit, Department of Experimental, Clinical and Biomedical Sciences, University of Florence, 50121, Florence, Italy.ORCID http://orcid.org/0000-0001-7424-6212
G GirasoleRheumatology Department, La Colletta" Hospital, ASL 3 Genovese, 16011, Arenzano, Italy.
M Di MonacoOsteoporosis Research Center, Fondazione Opera San Camillo, Presidio Di Torino, 10131, Turin, Italy.ORCID http://orcid.org/0000-0002-9519-608X
S GonnelliDepartment of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy.ORCID http://orcid.org/0000-0002-9914-0550
N MalavoltaCasa Di Cura Madre Fortunata Toniolo, and Centri Medici Dyadea, 40141, Bologna, Italy.ORCID http://orcid.org/0000-0002-6158-3671
S MinisolaU.O.C. Medicina Interna A, Malattie Metaboliche Dell'Osso Ambulatorio Osteoporosi E Osteopatie Fragilizzanti, Sapienza University of Rome, 00185, Rome, Italy.ORCID http://orcid.org/0000-0001-6525-0439
F VesciniUnit of Endocrinology and Metabolism, University-Hospital S. M. Misericordia, Udine, Italy.ORCID http://orcid.org/0000-0003-1892-9785
M RossiniRheumatology Unit, University of Verona, Policlinico GB Rossi, 37134, Verona, Italy.ORCID http://orcid.org/0000-0001-9692-2293
B FredianiDepartment of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy.ORCID http://orcid.org/0000-0002-2439-9250
I ChiodiniDepartment of Biotechnology and Translational Medicine, University of Milan, 20122, Milan, Italy.ORCID http://orcid.org/0000-0001-7594-3300
F AsciuttiAssociazione Italiana Malati Osteodistrofia Di Paget, Siena, Italy.
L GennariDepartment of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy. Luigi.gennari@unisi.it.ORCID http://orcid.org/0000-0001-6833-4232
University of Siena · ITSapienza University of Rome · ITUniversity of Milan · ITUniversity of Verona · ITAzienda Ospedaliera Universitaria Senese · ITOspedale Santa Maria della Misericordia di Udine · ITUniversity of Florence · ITUniversity of Naples Federico II · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPaget's disease of bone is a focal skeletal disorder causing bone deformities and impairing bone quality. Despite the prevalence of asymptomatic cases is increasing, the progression of the disease can lead to invalidating complications that compromise the quality of life. Doubts on clinical and therapeutic management aspects exist, although beneficial effects of antiresorptive drugs, particularly bisphosphonates are known. However, limited information is available from randomized controlled trials on the prevention of disease complications so that somewhat contrasting positions about treatment indications between expert panels from the main scientific societies of metabolic bone diseases exist. This task force, composed by expert representatives appointed by the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases and members of the Italian Association of Paget's disease of bone, felt the necessity for more specific and up to date indications for an early diagnosis and clinical management.

methodsThrough selected key questions, we propose evidence-based recommendations for the diagnosis and treatment of the disease. In the lack of good evidence to support clear recommendations, available information from the literature together with expert opinion of the panel was used to provide suggestions for the clinical practice. RESULTS AND

conclusionDescription of the evidence quality and support of the strength of the statements was provided on each of the selected key questions. The diagnosis of PDB should be mainly based on symptoms and the typical biochemical and radiological features. While treatment is mandatory to all the symptomatic cases at diagnosis, less evidence is available on treatment indications in asymptomatic as well as in previously treated patients in the presence of biochemical recurrence. However, given the safety and long-term efficacy of potent intravenous bisphosphonates such as zoledronate, a suggestion to treat most if not all cases at the time of diagnosis was released.

Indexed as

Osteitis DeformansBone Density Conservation AgentsDiphosphonatesHumansItalySocieties, MedicalBone Density Conservation AgentsDiphosphonatesBiochemical diagnosis of Paget’s disease of boneBone deformitiesClinical diagnosis of Paget’s disease of boneComplications of Paget’s disease of boneFragility fracturesGenetics of Paget’s disease of boneMetabolic bone diseasesPaget’s disease of bonePaget’s guidelinesRadiological diagnosis of Paget’s disease of boneTherapy of Paget’s disease of bone

Identifiers

PMID38488978
PMCPMC11142991
OpenAlexW4392864280

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.